Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6078163 | Journal of Investigative Dermatology | 2012 | 10 Pages |
Abstract
Skin cancer is the most prevalent cancer worldwide and is primarily caused by chronic UV exposure. Here, we describe the topical field-directed treatment of SKH1/hr mice with UVB-damaged skin with ingenol mebutate, a new topical drug shown to be effective for the treatment of actinic keratosis (AK). Application of 0.05% ingenol mebutate gel to photo-damaged skin resulted in a â70% reduction in the number of skin lesions that subsequently emerged compared with placebo treatment. Ingenol mebutate treatment also reduced the number of mutant p53 keratinocyte patches by â70%. The treatment resulted in epidermal cell death, acute inflammation, recruitment of neutrophils, hemorrhage, and eschar formation, all of which resolved over several weeks. Ingenol mebutate field-directed treatment might thus find utility in the removal of subclinical precancerous cells from UV-damaged skin. Field-directed treatment may be particularly suitable for patients who have AKs surrounded by UV-damaged skin.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Sarah-Jane Cozzi, Steven M. Ogbourne, Cini James, Heggert G. Rebel, Frank R. de Gruijl, Blake Ferguson, Joy Gardner, Thuy T. Lee, Thibaut Larcher, Andreas Suhrbier,